Diagnosis of glycogenosis type II

The diagnosis of glycogenosis type II is often complicated by the rarity of the condition and the heterogeneity of the clinical manifestations of the disease. It is a progressive, debilitating, and often fatal neuromuscular disorder that manifests as a continuum of clinical phenotypes, which vary with respect to organ involvement, age at onset, and severity. Early diagnosis requires both increased awareness among physicians regarding the clinical characteristics of the disease and fast and reliable acid alpha-glucosidase (GAA) enzyme activity assays to confirm the GAA deficiency. The clinical diagnosis of glycogenosis type II is confirmed by virtual absence (found in infants) and marked reduced activity (found in juveniles and adults) of GAA enzyme in blood samples, cultured fibroblasts, and muscle biopsies. This article specifically highlights the need for early recognition of the clinical manifestation of the disease in infants, juveniles, and adults. Descriptions of the main clinical features of the condition, as well as differential diagnosis are included. In addition, the tests required for a confirmed diagnosis are described, and use of muscle imaging to evaluate muscle pathology is reviewed.

[1]  D. Halley,et al.  Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating , 2008, Human mutation.

[2]  N. Raben,et al.  Role of autophagy in the pathogenesis of Pompe disease. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[3]  S. Marie,et al.  Deconstructing Pompe Disease by Analyzing Single Muscle Fibers: “To See a World in a Grain of Sand…” , 2007, Autophagy.

[4]  C. Angelini,et al.  Late‐onset GSDII with novel GAA gene mutation , 2007, Clinical genetics.

[5]  M. Ausems,et al.  Broad spectrum of Pompe disease in patients with the same c.-32-13T→G haplotype , 2007, Neurology.

[6]  B. Bembi,et al.  Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II , 2006, Human mutation.

[7]  David M. Rapoport,et al.  Pompe disease diagnosis and management guideline , 2006, Genetics in Medicine.

[8]  D. Orlikowski,et al.  Respiratory insufficiency and limb muscle weakness in adults with Pompe’s disease , 2005, European Respiratory Journal.

[9]  Yuan-Tsong Chen,et al.  Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. , 2005, Molecular genetics and metabolism.

[10]  W. Hop,et al.  Disease severity in children and adults with Pompe disease related to age and disease duration , 2005, Neurology.

[11]  W. Hop,et al.  Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. , 2005, Brain : a journal of neurology.

[12]  R. Howell,et al.  Pompe disease in infants and children. , 2004, The Journal of pediatrics.

[13]  A. Pichiecchio,et al.  Muscle MRI in adult-onset acid maltase deficiency , 2004, Neuromuscular Disorders.

[14]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[15]  G. Bassez,et al.  Evaluation of muscle glycogen content by 13C NMR spectroscopy in adult-onset acid maltase deficiency , 2003, Neuromuscular Disorders.

[16]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[17]  Susan C. Brown,et al.  Muscle MRI findings in a three-generation family affected by Bethlem myopathy. , 2002, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[18]  B. Byrne,et al.  Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). , 2002, Current molecular medicine.

[19]  P. Meikle,et al.  Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. , 2001, Clinical chemistry.

[20]  L. Sandkuijl,et al.  Glycogen Storage Disease Type II: Birth Prevalence Agrees with Predicted Genotype Frequency , 2000, Public Health Genomics.

[21]  A. Reuser,et al.  A diagnostic protocol for adult-onset glycogen storage disease type II , 1999, Neurology.

[22]  A. de Jager,et al.  Muscle computed tomography in adult‐onset acid maltase deficiency , 1998, Muscle & nerve.

[23]  A. Reuser,et al.  Genotype‐phenotype correlation in adult‐onset acid maltase deficiency , 1995, Annals of neurology.

[24]  Kayoko Saito,et al.  Computed tomography and magnetic resonance imaging of affected muscle in childhood acid α-glucosidase deficiency: a case report , 1993, Brain and Development.

[25]  M. Ōsawa,et al.  Computed tomography and magnetic resonance imaging of affected muscle in childhood acid alpha-glucosidase deficiency: a case report. , 1993, Brain & development.

[26]  M. Gorey,et al.  Evaluation of the lumbar spine in patients with glycogen storage disease: CT demonstration of patterns of paraspinal muscle atrophy. , 1991, AJNR. American journal of neuroradiology.

[27]  P. Trend,et al.  Acid maltase deficiency in adults. Diagnosis and management in five cases. , 1985, Brain : a journal of neurology.

[28]  A. Reuser,et al.  Biochemical genetics of the Lapland dog model of glycogen storage disease type II (acid alpha-glucosidase deficiency). , 1984, American journal of medical genetics.

[29]  L. Poenaru,et al.  White Blood Cells and the Diagnosis of α-Glucosidase Deficiency , 1980, Pediatric Research.

[30]  L. Poenaru,et al.  White blood cells and the diagnosis of alpha-glucosidase deficiency. , 1980, Pediatric research.

[31]  H. Hers.  α-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease) , 1963 .